Interleukin-6 and tumor necrosis factor-α in osteoimmunology: Aging, and anticytokine therapies
World Journal of Translational Medicine · 2026
DOI: 10.5528/wjtm.122119 ↗Kurz gefasst
Fachartikel in der Zeitschrift World Journal of Translational Medicine, 2026. Verfasst von Arunagiri Gunasekar und 6 weiteren Autor:innen. Die Arbeit nennt 102 Literaturangaben.
Abstract (Originalsprache)
Interleukin (IL)-6 and tumor necrosis factor (TNF)-α are key osteoimmunology cytokines that have extensive effects on bone remodeling and play a role in dysregulation in aging and inflammatory diseases. Both molecules affect the survival of osteoblasts (OBs), differentiation of osteoclasts (OCs), and osteocyte functions via pathways that include nuclear factor (NF)-κB activation, receptor activator of NF-κB ligand (RANKL)/osteoprotegerin imbalance, and dual IL-6 signaling (classical vs trans-signaling). All these mechanisms lead to bone resorption and hamper formation. Within the inflammaging context, the senescence-associated secretory phenotype (SASP) increases IL-6 and TNF-α, which stimulate immunosenescence, osteoporosis, rheumatoid arthritis erosions, and osteosarcopenia. This is a narrative review. The literature was identified through nonsystematic searches of PubMed and Google Scholar using terms related to IL-6, TNF-α, osteoimmunology, inflammaging, and anticytokine therapy, and relevant articles were selected and synthesized qualitatively. The review examines the IL-6 and TNF-α mechanistic pathways and crosstalk in osteoimmunology. It analyzes the pathogenic processes such as T-cell-derived RANKL, macrophage polarization changes, and OB apoptosis induced by TNF receptor 1 and IL-6 trans-signaling as well as assessing the aging immune alterations. This cytokine-induced crosstalk enhances RANKL production by stromal cells, osteocytes, and Th1 lymphocytes, and aging augments these effects due to myeloid bias and T regulatory cell dysfunction, ultimately decreasing bone mineral content and predisposing bone to fractures, as observed in postmenopausal osteoporosis and periodontitis. Anti-TNF- (etanercept and adalimumab) and anti-IL-6 (tocilizumab) therapeutic interventions that suppress OC activity, increase OB activity, and improve microarchitecture restore bone homeostasis. Observational studies have reported a lower fracture incidence with such therapies, although this estimate derives from nonrandomized data and warrants cautious interpretation. IL-6 interaction with TNF-α is the core principle of bone–immune crosstalk in aging and inflammation. New modalities are senolytics of SASP clearance, Janus kinase/NF-κB inhibitors, and precision medicine based upon cytokine profiling. Despite the promising results, there is still a problem with pharmacokinetics and safety in elderly patients. The interaction between IL-6 and TNF-α in bone–immune crosstalk is critical to further developing targeted interventions to counteract bone loss in old age and inflammation and enhance personalized treatment plans.
Zitieren
APA
Gunasekar, A., Jeyaraman, N., Chitra, S. B., Yudakar, V., Bharadwaj, S., Muthu, S., & Jeyaraman, M. (2026). Interleukin-6 and tumor necrosis factor-α in osteoimmunology: Aging, and anticytokine therapies. World Journal of Translational Medicine. https://doi.org/10.5528/wjtm.122119
Vancouver
Gunasekar A, Jeyaraman N, Chitra SB, Yudakar V, Bharadwaj S, Muthu S, et al. Interleukin-6 and tumor necrosis factor-α in osteoimmunology: Aging, and anticytokine therapies. World Journal of Translational Medicine. 2026. doi:10.5528/wjtm.122119
BibTeX
@article{Gunasekar2026,
author = {Gunasekar, Arunagiri and Jeyaraman, Naveen and Chitra, Sneha Babu and Yudakar, Vathani and Bharadwaj, Sanjeevi and Muthu, Sathish and Jeyaraman, Madhan},
title = {Interleukin-6 and tumor necrosis factor-α in osteoimmunology: Aging, and anticytokine therapies},
journal = {World Journal of Translational Medicine},
year = {2026},
doi = {10.5528/wjtm.122119}
}
EUVIMED